OPKO Slips To Loss In Q3 On Impact Of Discontinued Operations, Revenue Up
OPKO Health reported a Q3 net loss of $53.5M, or $0.07 per share, compared to a profit of $21.6M a year earlier. Revenue from continuing operations rose 16% to $65.4M. The company agreed to sell remaining BioReference operations to Labcorp for up to $872M. OPKO also issued $125M in senior secured royalty notes and provided updates on several clinical trials. Full-year 2026 revenue is expected between $268M and $278M.
How this was made
The 30-second read
Why it matters
The transaction is expected to strengthen OPKO's cash position and reduce ongoing losses, likely supporting the share price.
Market read
A material cash deal for a micro‑cap biotech provides a clear trading catalyst, with potential upside for OPKO shares.
What to watch
Contingent payments tied to Labcorp's 4Kscore test sales introduce uncertainty on total proceeds.
Background
OPKO Health reported Q3 loss and disclosed a major divestiture of its BioReference diagnostic business to Labcorp for $722 million, with up to $150 million in contingent payments.
Ticker impact
OPKO announced a $722 million cash sale of its BioReference diagnostic operations to Labcorp, a new transaction not previously disclosed.
likely upside as investors price in the cash proceeds and reduced loss exposure
A sizable cash acquisition of a discontinued business is a material catalyst for a micro‑cap biotech; the market typically reacts positively to such cash‑generating deals.
Market effects
Consolidation in the diagnostic services market may pressure peers, but OPKO's cash proceeds could set a benchmark for similar divestitures.
US biotech micro‑caps may see modest buying interest as cash‑rich deals emerge.
Limited to the niche diagnostic and biotech sector.
Counterpoint
The sale removes a revenue source; if integration risks for Labcorp materialize, OPKO could face future earnings volatility.
Key entities
- companyOPKO Health, Inc.
US‑listed biotech (ticker OPK) selling BioReference diagnostics.
- companyLabcorp
Buyer of BioReference assets.


